Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
rBUbnpQcwbzQuchu
